Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of ZG006 in Participants With Neuroendocrine Prostate Cancer
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Summary
This is a multicenter, open-label Phase II study, aimed at exploring the preliminary efficacy and safety of ZG006 in patients with advanced metastatic NEPC who have previously failed standard treatment.
Official title: A Phase II Study Evaluating the Preliminary Efficacy and Safety of ZG006 in Participants With Metastatic Neuroendocrine Prostate Cancer
Key Details
Gender
MALE
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-08
Completion Date
2027-12
Last Updated
2025-06-17
Healthy Volunteers
No
Conditions
Interventions
ZG006
ZG006 will be administered as an intravenous (IV) infusion.
Locations (1)
Fudan university shanghai cancer center
Shanghai, Shanghai Municipality, China